solo para uso en investigación
Cat. No.: S2907
| Dianas relacionadas | PKC ROCK Bcr-Abl |
|---|---|
| Otros TGF-beta/Smad Inhibidores | SB431542 RepSox (E-616452) Vactosertib (TEW-7197) LDN-193189 A-83-01 LDN-193189 Dihydrochloride Galunisertib (LY2157299) SRI-011381 (C381) LY2109761 SIS3 Hydrochloride |
| Líneas celulares | Tipo de ensayo | Concentración | Tiempo de incubación | Formulación | Descripción de la actividad | PMID |
|---|---|---|---|---|---|---|
| HFL1 cells | Function assay | 48 h | Antifibrotic activity in HFL1 cells assessed as inhibition of cell viability after 48 hrs by sulforhodamine B assay, IC50 = 0.71 μM. | 26896707 | ||
| LNCaP | Cell growth assay | 0, 0.1, 0.3 mg/ml | 3 days | PFD treatment significantly suppressed the growth of cells at 0.3 mg/ml | 30621175 | |
| PC-3 | Cell growth assay | 0, 0.1, 0.3 mg/ml | 3 days | PFD treatment significantly suppressed the growth of cells at 0.3 mg/ml | 30621175 | |
| E9 | Cell growth assay | 0, 0.1, 0.3 mg/ml | 3 days | PFD treatment significantly suppressed the growth of cells at 0.3 mg/ml | 30621175 | |
| F10 | Cell growth assay | 0, 0.1, 0.3 mg/ml | 3 days | PFD treatment significantly suppressed the growth of cells at 0.3 mg/ml | 30621175 | |
| AIDL | Cell growth assay | 0, 0.1, 0.3 mg/ml | 3 days | PFD treatment significantly suppressed the growth of cells at 0.3 mg/ml | 30621175 | |
| human intestinal fibroblasts (HIFs) | Function assay | 1 h | PFD inhibits HIFs differentiation and the collagen deposition induced by TGF-β1. | 30152848 | ||
| Haga clic para ver más datos experimentales de líneas celulares | ||||||
| Peso molecular | 185.22 | Fórmula | C12H11NO |
Almacenamiento (Desde la fecha de recepción) | |
|---|---|---|---|---|---|
| Nº CAS | 53179-13-8 | Descargar SDF | Almacenamiento de soluciones madre |
|
|
| Sinónimos | S-7701, AMR-69 | Smiles | CC1=CN(C(=O)C=C1)C2=CC=CC=C2 | ||
|
In vitro |
DMSO
: 37 mg/mL
(199.76 mM)
Ethanol : 37 mg/mL Water : Insoluble |
|
In vivo |
|||||
Paso 1: Introduzca la información a continuación (Recomendado: Un animal adicional para tener en cuenta la pérdida durante el experimento)
Paso 2: Introduzca la formulación in vivo (Esto es solo la calculadora, no la formulación. Por favor, contáctenos primero si no hay una formulación in vivo en la sección de Solubilidad.)
Resultados del cálculo:
Concentración de trabajo: mg/ml;
Método para preparar el líquido maestro de DMSO: mg fármaco predissuelto en μL DMSO ( Concentración del líquido maestro mg/mL, Por favor, contáctenos primero si la concentración excede la solubilidad del DMSO del lote del fármaco. )
Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadirμL PEG300, mezclar y clarificar, luego añadirμL Tween 80, mezclar y clarificar, luego añadir μL ddH2O, mezclar y clarificar.
Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadir μL Aceite de maíz, mezclar y clarificar.
Nota: 1. Por favor, asegúrese de que el líquido esté claro antes de añadir el siguiente disolvente.
2. Asegúrese de añadir el (los) disolvente(s) en orden. Debe asegurarse de que la solución obtenida, en la adición anterior, sea una solución clara antes de proceder a añadir el siguiente disolvente. Se pueden utilizar métodos físicos como el vórtice, el ultrasonido o el baño de agua caliente para ayudar a la disolución.
| Targets/IC50/Ki |
TGF-β
(Cell-free assay) |
|---|---|
| In vitro |
Pirfenidone (< 300 μg/mL) suppresses the proinflammatory cytokine tumor necrosis factor-α (TNF-α) by a translational mechanism in RAW264.7 cells, which is independent of activation of the mitogen-activated protain kinase (MAPK) 2, p38 MAP kinase, and c-Jun N-terminal kinase (JNK). This compound (< 10 mM) leads to reduced glioma cell density in concentration-dependent manner in LN-18, T98G, LNT-229 and LN-308 cell lines. It (< 5 mM) reduces TGF-β bioactivity by affecting TGF-β2 mRNA expression and processing of pro-TGF-β in CCL-64 cells. This chemical (< 8.3 mM) inhibits the activity of recombinant furin and downregulates the expression of MMP-11 in a dose-dependent manner in LN-308 cells. |
| In vivo |
Pirfenidone (250 mg/kg) potently inhibits the production of the proinflammatory cytokines, TNF-alpha, interferon-gamma, and interleukin-6, but enhances the production of the anti-inflammatory cytokine, interleukin-10, in mice. This compound (250 mg/kg/day) ameliorates cyclosporine-induced fibrosis by about 50% and decreases TGF-beta1 protein expression by 80% in Sprague-Dawley rats receiving a low-salt diet. It (400 mg/kg/day) inhibits heat shock protein 47-positive cells and myofibroblasts, the principal cells responsible for the accumulation and deposition of extracellular matrix seen in pulmonary fibrosis in ICR mice intravenously injected with bleomycin. This chemical (0.5%, liquid diet) treatment reduces the degree of liver injury in rats, as determined by alanine aminotransferase values and necro-inflammatory score, which is associated with reduced hepatic stellate cells proliferation and collagen deposition. This compound (0.5%, liquid diet) administration downregulates dimethylnitrosamine induced transcripts levels of procollagen alpha1(I), TIMP-1 and MMP-2 by 50-60% in rats, and this is associated with a 70% reduction in collagen deposition. |
Referencias |
|
| Métodos | Biomarcadores | Imágenes | PMID |
|---|---|---|---|
| Immunofluorescence | α-SMA SMAD4 / SMAD2 / SMAD3 F-actin / β-catenin / Vimentin |
|
22132230 |
(datos de https://clinicaltrials.gov, actualizado el 2024-05-22)
| Número NCT | Reclutamiento | Condiciones | Patrocinador/Colaboradores | Fecha de inicio | Fases |
|---|---|---|---|---|---|
| NCT05676112 | Withdrawn | Pulmonary Fibrosis |
Boehringer Ingelheim|China-Japan Friendship Hospital |
December 29 2023 | -- |
| NCT06070610 | Completed | Healthy |
Boehringer Ingelheim |
November 8 2023 | Phase 1 |
| NCT05713292 | Active not recruiting | COVID-19 Pneumonia |
Capital Medical University |
December 30 2022 | Phase 3 |
| NCT05505409 | Recruiting | Pirfenidone|Connective Tissue Diseases|Interstitial Lung Disease |
Qilu Hospital of Shandong University |
June 22 2022 | Phase 4 |
Pregunta 1:
I'd like to know how to use your 50mg dose of it to make a solution for intraperitoneal injection in a mouse. Could you give me some advice?
Respuesta:
For I.P. injection, it can be dissolved in 2% DMSO+30% PEG 300+ddH2O at 10 mg/ml clearly. When preparing the solution, please dissolve this compound in DMSO clearly first. Then add PEG, after they mixed well, then dilute with water.